should i switch from tirzepatide to semaglutide Switching Semaglutide: What to Expect Switching from full dose Semaglutide

BPC-157: 250 to 300 mcg subcutaneously twice daily near the affected level

Micronized lifestyle mix ingredients The protein shake component provides more transparent information

Such improvement may be due to enhanced dopaminergic neurotransmission as studies have suggested that dopaminergic neurotransmission is involved in the manifestation of spontaneous alternation behavior

Clinical Trial Results STEP Trials (Semaglutide) The STEP program studied semaglutide 2.4 mg weekly in overweight/obese adults: STEP 1 : 16.9% average weight loss over 68 weeks vs 2.4% placebo STEP 2 (T2D patients): 9.6% weight loss STEP 3 (with behavioral therapy): 16.0% weight loss STEP 5 (2-year data): 15.2% sustained weight loss SURMOUNT Trials (Tirzepatide) The SURMOUNT program studied tirzepatide at 5mg, 10mg, and 15mg weekly: SURMOUNT-1 : 20.9% average weight loss at 15mg over 72 weeks vs 3.1% placebo SURMOUNT-2 (T2D patients): 14.7% at 15mg SURMOUNT-3 (with lifestyle intervention): 26.6% at highest dose SURMOUNT-4 (maintenance): continued weight loss vs weight regain on placebo Head-to-Head No large head-to-head trial has directly compared them at optimal doses for weight loss